




## SUPPLEMENTARY MATERIAL




**Figure S1. BM-derived murine macrophages do not express LRP8 (ApoER2).** Total RNA was extracted from BM-derived murine macrophages or endothelial progenitor cells (EPC; as a control) using Absolutely RNA miniprep kit (Stratagene) according to the manufactures' instructions. One microgram of total RNA was used for cDNA synthesis using Superscript III and random hexamers (Invitrogen). RT-PCR was performed using AmpliTaq Polymerase and the following primers: LRP8: 5'-GTGATGATCAGAGGGACTGC-3' and 5'-AAGCCGATCTTGAGGTCAGT-3';  $\beta$ -actin: 5'-AGTGTGACGTTGACATCCGT-3' and 5'-TGCTAGGAGCCAGAGCAGTA-3'. The PCR reaction was done in 25  $\mu$ l solution containing 12.5  $\mu$ l PCR Master Mix, 10 ng cDNA, and 400 nM of each primer, with the following settings: activation 95  $^{\circ}$ C for 2 min, 35 cycles of 94  $^{\circ}$ C for 30s, 57  $^{\circ}$ C for 30s, and 72  $^{\circ}$ C for 30s, followed by 72  $^{\circ}$ C for 10 min. The PCR products were analyzed on 2% agarose gel. Data shown are representative of two independent experiments.





**Figure S2. The IL-6 suppressive activity of APC is independent of integrin  $\beta$ 1, integrin  $\beta$ 3, ApoER2 or EGFR activity.** LPS-stimulated *WT* and *CD11b<sup>-/-</sup>* BM-derived macrophages were treated with (filled bar) or without (open bar) 5  $\mu$ g/ml APC in the presence of blocking antibodies/inhibitors for integrin  $\beta$ 1 (MFR5; 20  $\mu$ g/ml), integrin  $\beta$ 3 (2C9.G2; 20  $\mu$ g/ml), ApoER2 (RAP; 1  $\mu$ M) or EGFR (PP3; 10  $\mu$ M) at 37°C for 20 hours. IL-6 concentration in the conditioned media was determined by ELISA. Data shown were means  $\pm$  S.D. of duplicate wells.




**Figure S3. CD11b is critical to macrophage adhesion to GD-APC.** *WT* BM-derived macrophages were allowed to adhere to hGD-APC-coated 24-well plates in the presence of function-blocking antibodies/inhibitors for CD11b/CD18 (M1/70; 20  $\mu$ g/ml), integrin  $\beta$ 1 (MFR5; 20  $\mu$ g/ml), integrin  $\beta$ 3 (2C9.G2; 20  $\mu$ g/ml), ApoER2 (RAP; 1  $\mu$ M) or control IgG. After washing, the number of adherent cells was quantified by absorbance at 570 nm of crystal violet-stained plates. The critical role of CD11b was further confirmed by the inability of *CD11b<sup>-/-</sup>* BM-derived macrophages to adhere to GD-APC. Data shown represent means  $\pm$  SD of duplicate experiments.




**Figure S4. Macrophage adhesion to hAPC can be blocked by soluble hAPC and mAPC.** WT and CD11b<sup>-/-</sup> BM-derived macrophages were allowed to adhere to hAPC-coated 24-well plates in the presence of PBS, 10 nM CD11b/CD18-specific antagonist (NIF) or 20 µg/ml blocking antibody (M1/70), 20 µg/ml hAPC, 20 µg/ml hGD-APC, or 20 µg/ml mAPC. After washing, the number of adherent cells was quantified by absorbance at 570 nm of crystal violet-stained plates. Data shown represent means ± SD of duplicate samples.




**Figure S5. CD11b deficiency does not affect PAR-1 expression on BM-derived macrophages and vice versa.** A) PAR-1 expression. Total RNA and cell lysates were prepared using *WT* and *CD11b<sup>-/-</sup>* BM-derived macrophages. RT-PCR was conducted using PAR-1 and  $\beta$ -actin-specific primers (see Table S1). Western blot was performed using rabbit anti-PAR-1 (H-111) and mouse anti- $\beta$ -actin antibody, respectively. B) Surface CD11b expression. *WT* and *Par1<sup>-/-</sup>* BM-derived macrophages were stained with FITC-conjugated anti-CD11b mAb (M1/70). After washing, CD11b surface expression was analyzed by flow cytometry. Mean fluorescent intensity (MFI) was calculated using the FACScan program.




**Figure S6. CD11b is critical to protection of endotoxemic mice by mAPC.** WT (A) or *CD11b*<sup>-/-</sup> (B) mice were injected i.p. with a single dose (LD<sub>90</sub>) of LPS, followed by two i.v. injections of 10 μg mAPC (□) or PBS (○) at 20 min and 8 hours post-LPS challenge. Survival was determined over a period of 12 days and shown in Kaplan–Meier plots. Log rank test between mAPC and PBS: p=0.048, n=8 for WT and p=0.767, n=8 for *CD11b*<sup>-/-</sup> mice.




**Figure S7. CD11b/CD18 but not the  $\beta_1$  integrins is critical to macrophage adhesion to APC.** BM-derived macrophages were allowed to adhere to fibronectin (5  $\mu\text{g/ml}$ ) or hAPC (20  $\mu\text{g/ml}$ )-coated 24-well microtiter plate in the presence of 20 nM NIF, 10  $\mu\text{g/ml}$  MBP-invasin or 5  $\mu\text{g/ml}$  APC for 40 min at 37°C. After washing, adherent cells were determined by staining cells with 0.5% Crystal Violet and measuring absorption at 570nm. The number of adherent macrophages in the absence of inhibitors was assigned 100%. Data shown are means  $\pm$  SD of duplicate experiments.



**Figure S8. mGD-APC exhibits similar *in vitro* suppressive activity toward macrophages to mAPC.** BM-derived macrophages were left untreated (-LPS) or stimulated with 50 ng/ml LPS in the presence of 0.09  $\mu$ M mAPC, mGD-APC, hGD-APC, DFP-treated hGD-APC or vehicle control ("-"). Twenty hours later, IL-6 concentration in the conditioned media was determined by ELISA. Data shown were means  $\pm$  S.D. of duplicated samples and are representative of two independent experiments.



**Figure S9. APC suppression of leukocyte infiltration in the lung in endotoxemic mice is dependent on CD11b.** *WT* or *CD11b<sup>-/-</sup>* mice were injected i.p. with a single LD<sub>90</sub> dose of LPS, followed by i.v. injections of 10 µg hAPC, 10 µg hGD-APC or PBS. Twenty hours later, mice were sacrificed, perfused with PBS, and then fixed in 1% PFA. Lungs were collected, embedded in paraffin, cut into 5 µm-thick tissue sections, and stained with H&E. The number of infiltrating leukocytes was determined using NIH ImageJ by counting 5 randomly selected view fields per section. Data shown were means ± S.E.M of three mice. \*, p<0.01, two-tailed Student's t-test.



**Figure S10. The two-dose late intervention regimen is superior to the early intervention regimen in GD-APC suppression of IL-6 production *in vivo*.** In the early intervention regimen (black bar), WT mice were injected i.v. with 10  $\mu$ g hGD-APC, followed by i.p. injection of a single LD<sub>90</sub> dose of LPS. In the two-dose late intervention regimen (gray bar), WT mice were injected i.p. with a single LD<sub>90</sub> dose of LPS, followed by two intravenous injections of 10  $\mu$ g hGD-APC at 20 min and 8 hours post-LPS challenge. Twenty hours later, mice were sacrificed and IL-6 concentrations in the blood were determined by ELISA. Data shown were means  $\pm$  S.D. \*, P<0.001, LPS vs. LPS+hGD-APC; n=3-4.

**Table s1. Primers used for qRT-PCR**

β-Actin	NM_007393	Forward (5' to 3')	AGTGTGACGTTGACATCCGT
		Reverse (5' to 3')	TGCTAGGAGCCAGAGCAGTA
ApoER2	NM_001080926	Forward (5' to 3')	GTGATGATCAGAGGGACTGC
		Reverse (5' to 3')	AAGCCGATCTTGAGGTCAGT
TNF-α	NM_013693	Forward (5' to 3')	ATGAGAAGTTCCCAAATGGC
		Reverse (5' to 3')	CTCCACTTGGTGGTTTGCTA
IL-6	NM_031168	Forward (5' to 3')	CTCTGGGAAATCGTGAAAT
		Reverse (5' to 3')	CCAGTTTGGTAGCATCCATC
IL-12A	NM_008351	Forward (5' to 3')	GTCTTAGCCAGTCCCGAAAC
		Reverse (5' to 3')	CAGGTCTTCAATGTGCTGGT
NOS2A	NM_010927	Forward (5' to 3')	GGAGCATCCCAAGTACGAGT
		Reverse (5' to 3')	CCCATGTACCAACCATTGAA
STAT3	NM_011486	Forward (5' to 3')	GAGAAGCAGCAGATGTTGGA
		Reverse (5' to 3')	CATGTCTCCTTGGCTCTTGA
NFκB1	NM_008689	Forward (5' to 3')	GGAGAAGGCTGGAGAAGATG
		Reverse (5' to 3')	GCTCATAACGGTTTCCCATT
TRAIL	NM_009425	Forward (5' to 3')	TGCAGGTTAAGAGGCAACTG
		Reverse (5' to 3')	GTGAGCTGCCACTTTCTGAG
Wnt5A	NM_009524	Forward (5' to 3')	CAAATAGGCAGCCGAGAGAC
		Reverse (5' to 3')	CAGCCACAGGTAGACAGCTC
BCL-3	NM_033601	Forward (5' to 3')	TGCTGAACCTGCCTACTCAC
		Reverse (5' to 3')	GTTATTCTGGACCACAGCGA